This directory serves as a resource listing of active biotech that develop therapeutics, diagnostics and/or medtech. The companies listed in this directory are not representative of the companies that are active members of the Biotech and Money community.
Add / Amend your company listing for free
(only active biotech ie. therapeutic, diagnostic and medtech companies are eligible for listing)
New Zealand
Genesis Research and Development Corporation Limited, formerly Genesis Research & Development Corp., Ltd. is a biotechnology company, with a primary focus on the development of therapeutics for the treatment of cancer and diseases of the immune system. The company is developing gene silencing technology called RNA interference (RNAi), to target the growth and drug resistance of cancer cells.
Innate Immunotherapeutics Limited is a public unlisted biotech company based in Auckland, NZ. The Company has designed and manufactured a unique immunomodulator microparticle technology. This technology can be used to induce the human immune system to fight certain cancers and infections, or turn off certain immune mechanisms which lead to autoimmune diseases such as Multiple Sclerosis. The same technology can be used in the design of better vaccines to potentially treat or prevent diseases such as influenza, cancer, malaria, or tuberculosis.
LCT is a New Zealand based biotechnology company focused on developing living cell products for the treatment of diabetes, neurological disease and haemophilia. LCT is developing NTCELL, a choroid plexus cell product which is currently in preclinical development to treat neurodegenerative diseases such as Parkinson's disease, Huntington's disease, stroke, and hearing loss.
Pacific Edge Limited is a New Zealand based cancer diagnostic company specializing in the discovery and commercialization of diagnostic and prognostic technology for the early detection and monitoring of cancer. Pacific Edge's first commercially available product, Cxbladder, is a non-invasive laboratory test for the detection of bladder cancer.